TCF4 Mutations Disrupt Synaptic Function Through Dysregulation of RIMBP2 in Patient-Derived Cortical Neurons

• Published in: Biological psychiatry (1969) 2024-04, Vol.95 (7), p.662-675
• Main Authors: Davis, Brittany A., Chen, Huei-Ying, Ye, Zengyou, Ostlund, Isaac, Tippani, Madhavi, Das, Debamitra, Sripathy, Srinidhi Rao, Wang, Yanhong, Martin, Jacqueline M., Shim, Gina, Panchwagh, Neel M., Moses, Rebecca L., Farinelli, Federica, Bohlen, Joseph F., Li, Meijie, Luikart, Bryan W., Jaffe, Andrew E., Maher, Brady J.
• Format: Article
• Language: English
• Subjects: Animals; Autism spectrum disorder; Autism Spectrum Disorder - genetics; Autism Spectrum Disorder - metabolism; Human induced pluripotent stem cell (hiPSC); Humans; Induced Pluripotent Stem Cells - metabolism; Intellectual Disability - genetics; Intellectual Disability - metabolism; Mutation; Neurons - metabolism; Pitt-Hopkins syndrome (PTHS); Presynapse; Psychiatric disorder; Transcription factor 4 (TCF4); Transcription Factor 4 - genetics; Transcription Factor 4 - metabolism
• ISSN: 0006-3223; 1873-2402
• DOI: 10.1016/j.biopsych.2023.07.021

Genetic variation in the TCF4 (transcription factor 4) gene is associated with risk for a variety of developmental and psychiatric conditions, which includes a syndromic form of autism spectrum disorder called Pitt-Hopkins syndrome (PTHS). TCF4 encodes an activity-dependent transcription factor that is highly expressed during cortical development and in animal models has been shown to regulate various aspects of neuronal development and function. However, our understanding of how disease-causing mutations in TCF4 confer pathophysiology in a human context is lacking. To model PTHS, we differentiated human cortical neurons from human induced pluripotent stem cells that were derived from patients with PTHS and neurotypical individuals. To identify pathophysiology and disease mechanisms, we assayed cortical neurons with whole-cell electrophysiology, Ca2+ imaging, multielectrode arrays, immunocytochemistry, and RNA sequencing. Cortical neurons derived from patients with TCF4 mutations showed deficits in spontaneous synaptic transmission, network excitability, and homeostatic plasticity. Transcriptomic analysis indicated that these phenotypes resulted in part from altered expression of genes involved in presynaptic neurotransmission and identified the presynaptic binding protein RIMBP2 as the most differentially expressed gene in PTHS neurons. Remarkably, TCF4-dependent deficits in spontaneous synaptic transmission and network excitability were rescued by increasing RIMBP2 expression in presynaptic neurons. Taken together, these results identify TCF4 as a critical transcriptional regulator of human synaptic development and plasticity and specifically identifies dysregulation of presynaptic function as an early pathophysiology in PTHS.